Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
about
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerAnti-angiogenic agents in metastatic colorectal cancerTRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver MetastasesMultidisciplinary approach of colorectal cancer liver metastases.Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseBevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysisDPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agentsA Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerPhase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.Advances and new perspectives in the treatment of metastatic colon cancer.First-line chemotherapy for mCRC—a review and evidence-based algorithm.Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal CancerFOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis.Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis.Current treatment options for patients with initially unresectable isolated colorectal liver metastases.The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma.Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis.Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.Recent advances in treatment for colorectal liver metastasis.Comparison of the guidelines for colorectal cancer in Japan, the USA and Europe.Prognostic factors of hepatectomy in initially unresectable colorectal liver metastasis: Indication for conversion therapySynchronous liver metastases in patients with rectal cancer: can we establish which treatment first?
P2860
Q26748924-1F8DDB6D-E574-4B87-AA14-4C20CF98D5E5Q26801911-B2C67B77-3518-4CD6-88A3-18F50A310744Q30855372-C68FF2CD-7962-4005-A1F1-908516C1F40EQ33770802-4403EFC5-3D0E-4FA3-817B-B3A9D1DBACDAQ33779859-6738BEEC-BA23-4BAA-865A-60FA3F4973BAQ34492273-87709B5D-6122-4B62-A36D-4D5069D5D9CBQ35585759-D8368D6F-DE57-4283-989E-6FFBE14ECC79Q35817933-FD23B6FB-82C6-46DA-A3EB-8CF8952DF208Q35826810-CB32C858-4099-46A8-AF39-448F7409EFECQ36072520-FB152711-2E8B-448D-A912-A0FF2B2EF393Q36343047-188A238D-A279-4D69-9BA0-08002F8CD2A6Q36673499-6385546A-9237-41B2-A0F8-65083D01BB4BQ36706109-65468CA6-8163-4565-807C-7FAECF80282DQ37432618-AE961614-000A-4B98-B5DE-84875EFBE62EQ38229589-7F2427F4-F7CB-47EF-A39A-2CA89CB7F1FFQ38555200-D2A1B5B7-DC06-4EAE-8CBA-AE9D29F0AFB4Q38617495-B82DADE8-0057-4B7C-8062-70A1DB69AB9BQ38674714-E29A2294-BD30-493A-8A42-84CFB2CE63CCQ38764838-B44FD0C5-0CA4-41E5-8290-BBF71E5A95CCQ38811461-6A74DAEE-0195-4540-A9BB-C205979AEF84Q41882575-062ECA08-C6D9-4780-8978-DB9C634AADEDQ41947158-6C66D588-F447-4F00-83FA-E06F592D8C0DQ42540076-75DE3B1E-773D-4E19-9730-6B7DD01B5EE3Q48197461-CBDDB2B1-7261-4E10-ADC5-D19B7A905D54Q50041173-6A87B512-C6A4-4772-9F4D-CB33AF67096FQ51193100-329F2C87-DF89-45DD-A57F-F4601586DC04Q52659461-01ADA023-AACD-45BF-982B-361DBC336E12Q52682270-593387D2-5E47-42C1-BFAF-B41DC0E75F72Q55246010-D7E0070E-E20B-4D02-A468-A03A7EDFAB7BQ55362337-84B5B061-F194-404A-B25C-978070E34680Q57788525-65ADB514-D270-4C3A-81AE-DBDC1839169AQ58797711-29005BAA-918E-4288-9482-8CE90C2B0CEF
P2860
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Bevacizumab plus mFOLFOX-6 or ...... nal randomised phase II trial.
@en
type
label
Bevacizumab plus mFOLFOX-6 or ...... nal randomised phase II trial.
@en
prefLabel
Bevacizumab plus mFOLFOX-6 or ...... nal randomised phase II trial.
@en
P2093
P2860
P921
P356
P1433
P1476
Bevacizumab plus mFOLFOX-6 or ...... onal randomised phase II trial
@en
P2093
D Waterkamp
J Bridgewater
P García Alfonso
S Lasserre
P2860
P304
P356
10.1093/ANNONC/MDU580
P577
2014-12-23T00:00:00Z